CD8A and neoplasm: In the context of tumor-associated myeloid-derived suppressor cells (tumor-MDSCs), the downregulation of PERK transforms these cells into myeloid cells that activate CD8+ T cell-mediated anti-cancer immunity, featuring compromised NRF2-driven antioxidant capabilities and disrupted mitochondrial respiratory balance.